CNS Tumor clinical trials at UC Cancer
2 research studies open to eligible people
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With No Curative First-Line Treatment Option, Recurrent or Refractory Solid Tumors And Primary Cns Tumors, With or Without Trk, Ros1, or Alk Fusions
open to eligible people ages up to 22 years
This is a 5-part, open-label, Phase 1/2 multicenter, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; 4) non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements; and 5) patients who are otherwise eligible but unable to swallow capsules. The study is designed to explore the safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetics, and antitumor activity of entrectinib.
at UCSF
Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry
open to eligible people ages 18 years and up
This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.
at UCLA UC Irvine UCSF
Last updated: